Darolutamide Showed Similar Benefits for Black/African American Patients as Observed in the Overall Population of the ARAMIS Trial
PHILADELPHIA – Black/African American patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide (Nubeqa) had...